# A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).

> **NCT03306394** · PHASE3 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 907 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trifluridine/Tipiracil hydrochloride (S95005)

## Key facts

- **NCT ID:** NCT03306394
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-18
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 907 (ACTUAL)
- **Last updated:** 2024-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03306394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03306394, "A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03306394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*